TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05695703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Strength Training Group
Description: The participants of experimental group will perform core strength training regime for 6 weeks (3 days per week). Each exercise session will last for a period of 45 mins, the exercises would be performed in 3 sets of 5 repetitions with 5 seconds hold time and 10 seconds rest between each repetition and a minutes rest in between each set.~Following exercises would be performed :~Bridge, Crunch, Plank, Side Plank, Mountain Climb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training Group
Description: The participants of conventional group will perform following exercises :~Running (10 repetitions X 3 sets), Jogging (10 repetitions X 3 sets), Stretching (10 repetitions X 3 sets)~Rest between Exercises : 10-15 Seconds Rest between Set of Exercises : 30-60 Seconds Cricketers will receive exercises for 8 weeks. There will be 3 sessions per week.
Study: NCT05447273

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-parametric, functional magnetic resonance imaging (MRI)
Description: Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.
Study: NCT06441409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.~Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day.
Study: NCT06416631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: artificial intelligence based screw planning
Description: artificial intelligence technology helps to plan screws in robot assisted spinal surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: manually screw planning
Description: the screw trajcetories are manually planned
Study: NCT06105606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AveCure Flexible Microwave Ablation Probe
Description: Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
Study: NCT06443294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation video series.
Description: The intervention in this study is a series of six videos totally approximately 40 minutes. These videos are led by a doctoral psychology student with experience in working with tobacco smokers. Videos utilize empirically-supported strategies for smoking cessation.
Study: NCT04624763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met:~   1. Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~  2. If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~  3. LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is \< 10ms;~  4. A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
Study: NCT05882929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watching Cartoons
Description: The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ball spin
Description: ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
Study: NCT06419491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partner notification by a trained counsellor
Description: One (or more if needed) interview with a partner notification trained counsellor is offered to index patients. During the interview, the counsellor gives information on partner notification, helps the index patients to remember their partners, to assess their HIV/sexually transmitted infection exposure and explains options to notify them.~During the interview, the index patient can choose to entrust the notification of some of their partners to the counsellor. However, according to French law, provider referral is permitted only when it is anonymous. Therefore, this option is reserved to partners with a lot of partners in order to limit the risk of identifying the index patient
Study: NCT04644029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral 60 mg tablet administered once monthly during Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to FTC/TDF
Description: 0 mg tablet administered once daily during Part 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ISL
Description: 0 mg tablet administered orally once monthly in Part 1.
Study: NCT04531865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 intravenously on day 0 and day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 intravenously on day 0 and day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets matching Mycophenolate Mofetil
Description: Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
Study: NCT05158621

Intervention type: PROCEDURE
Intervention: blood collection for research (next generation sequencing [NGS])
Description: participants will have whole blood collected for NGS

Intervention type: PROCEDURE
Intervention: blood collection for research (next generation sequencing [NGS])
Description: participants will have whole blood collected for NGS

Intervention type: PROCEDURE
Intervention: blood collection for research (HLA typing)
Description: participants will have whole blood collected for HLA typing

Intervention type: PROCEDURE
Intervention: blood collection for research (HLA typing)
Description: participants will have whole blood collected for HLA typing

Intervention type: PROCEDURE
Intervention: blood collection for research (circulating tumor DNA [ctDNA])
Description: participants will have whole blood collected for ctDNA detection
Study: NCT05831800

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable bioimpedance sensor
Description: The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
Study: NCT05469646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study: NCT04789304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study: NCT05453136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TS-142
Description: Participants received repeated doses of placebo to TS-142 (oral tablet)
Study: NCT06120608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel dietary approach focused on restricting the intake of highly bioavailable potassium
Description: Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional approach
Description: Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
Study: NCT05552196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: Ponesimod tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: Ponesimod tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine tablet will be administered orally.
Study: NCT05198895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR)
Description: NIR spectral assessment of glycated nail keratin vs glycated haemoglobin (HbA1c)
Study: NCT04341935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5 mg Linagliptin administered by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin regimen
Description: Standard of care insulin regimen as per hospital protocol
Study: NCT04718922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate 0.12 % Mouthwash
Description: Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
Study: NCT05197439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The 4.8ug/kg dexmedetomidine will be diluted into 100ml and pump 2ml/h at the beginning of the second of DBS and last for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT06429904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab+ NALIRIFOX
Description: Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX
Study: NCT05029661

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid ultrasound
Description: * Ultra-COMPASS measurements (longitudinal + cross-sectional) Shear wave elastography: plaque stiffness Strain elastrogaphy: plaque deformation B-mode visualization: geometry~* Intima-media thickness~* Pulse wave velocity
Study: NCT05319548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple-Red Carrot Juice
Description: Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple-Red Carrot Juice
Description: Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple-Red Carrot Juice
Description: Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Carrot Juice
Description: Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Carrot Juice
Description: Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Carrot Juice
Description: Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple Carrot Juice
Description: Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple Carrot Juice
Description: Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purple Carrot Juice
Description: Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
Study: NCT06293742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered orally.
Study: NCT06514287

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individualized intervention
Description: It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
Study: NCT04483414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga PSMA-11 injection
Description: Injection of 68Ga PSMA-11

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after 68Ga PSMA-11 injection
Study: NCT05449899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
Study: NCT05846750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression
Study: NCT05194514

Intervention type: DEVICE
Group type: OTHER
Intervention: SherpaPak™ Device
Description: The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Storage
Description: FDA-approved method for organ procurement
Study: NCT06144255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken.
Study: NCT04821063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357 10 mg/mL
Description: Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357 10 mg/mL
Description: Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose: 20 mL; Dosage form: suspension; Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Hydrochloride
Description: Dose: 400 mg; Dosage form: tablet; Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 30 mL; Dosage form: suspension; Route of administration: oral
Study: NCT05181267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: Subjects fast from after dinner and throughout the next day, i.e., 36 hours of fasting, after which they are allowed to eat as usual until dinner the same day. Then they fast again for 36 hours, and this regimen will continue for three entire weeks.
Study: NCT06435013

Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
Study: NCT05201092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Lu AG06466
Description: \[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
Study: NCT06059040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: eliminating gastric residual volume monitoring
Description: eliminating gastric residual volume monitoring from routine care
Study: NCT04960215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A soft gelatin capsule containing soy oil, 5 capsules a day.